Eli Lilly & Company Chairman and CEO Dave Ricks sheds light on growth and success, the increase in weight loss drug ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings ... Joining me on today's call are Dave Ricks, Lilly's chair and CEO; Dr. Dan Skovronsky, chief scientific officer and ...

Eli Lilly CEO David Ricks, also an Adobe director, paid $1 million on Jan. 28 for 2,250 shares of the software company. Bill Gates Says He Donated $100 Billion Of His Wealth To Charitable Causes ...

We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands ...

"2024 was a highly successful year for Lilly," said Eli Lilly CEO David Ricks in a statement. In addition to success with its weight-loss drugs, Ricks cited "major data readouts for tirzepatide in ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks that Jim Cramer discussed. In the episode of CNBC's Squawk on the Street ...

The CEO acknowledged the “turbulence” that ... Editor's note: This story has been updated with executive comments from Eli Lilly's fourth-quarter and full-year 2024 earnings call.